Top 20 Life Sciences Deals of 2025 

Shots: 

• From AI-powered discovery to next-generation biologics and gene editing, 2025 was a blockbuster year for life sciences dealmaking. Pharma and biotech companies signed multibillion-dollar partnerships and acquisitions to accelerate innovation across oncology, cardiometabolic diseases, neurology, and rare disorders. 
• Platform technologies dominated the deal landscape, with big pharma securing access to cutting-edge modalities from bispecific antibodies and siRNA therapeutics to AI-driven drug discovery and gene editing, reflecting a shift toward scalable innovation engines rather than single assets.  
• Three mega deals ultimately stole the limelight in 2025. BioNTech and Bristol Myers Squibb signed an ~$11.1B collaboration for the bispecific antibody BNT327, followed by Innovent Biologics and Takeda’s ~$11.4B oncology partnership. Taking the top spot, Jiangsu Hengrui Pharmaceuticals and GSK announced the year’s largest deal, a ~$12.5B collaboration to advance up to 12 innovative programs across multiple therapeutic areas. 

The Top 20 Life Sciences Deals of 2025 report has been published in partnership with our data partner DealForma who has provided us with the 2025 deals data. 

20. Tanabe Pharma Business Unit Purchase Deal with Shionogi & Co. 

Deal Date: 22 Dec 2025 

Deal Value: $2.5B  

• Tanabe Pharma entered into an agreement with Shionogi & Co. in December 2025 for the purchase of Tanabe’s RADICAVA business, including global rights to RADICAVA ORS (edaravone oral suspension) and the intravenous RADICAVA formulation. As part of the transaction, Tanabe established a new company to hold the RADICAVA assets, which will be acquired by Shionogi as a wholly owned subsidiary, strengthening Shionogi’s commercial presence in the rare disease segment. 
• Under the terms of the agreement, Shionogi will pay a lump-sum consideration of approximately ~$2.5B to Tanabe Pharma upon completion of the transaction. In addition, Tanabe may receive royalties on future sales of RADICAVA products under certain conditions, while the acquired entity will operate within Shionogi’s US business to support global commercialization of the therapy.  
• The acquisition centers on RADICAVA ORS (edaravone), an approved therapy for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with limited treatment options.   

Key Takeaways 

• The deal significantly expands Shionogi’s presence in the rare disease market through an established ALS therapy 
• RADICAVA provides an immediate commercial revenue stream, with the business expected to generate around ~$700M in annual global sales 
• The acquisition also builds a rare disease commercial infrastructure to support future launches from Shionogi’s pipelin 

19. Datavault AI Development and Commercialization Deal with Scilex Holding 

Deal Date: 4 Nov, 2025 

Deal Value: $2.56B  

• Datavault AI signed a worldwide exclusive development and commercial licensing agreement with the right to sublicense with Scilex Holding Company in November 2025, giving Scilex access to Datavault’s AI-driven blockchain and data monetization technology for use in biotech and biopharma applications. The partnership focuses on building a Biotech Exchange platform to securely tokenize and commercialize real-world biomedical assets such as genomic data, diagnostics, therapeutics, and drug-related datasets. 
• Under the agreement, Datavault AI will receive ~$10M in upfront licensing fees, structured as four quarterly payments of ~$2.5M each. The company is also eligible for up to ~$2.55B in sales-based milestone payments, along with a ~5% royalty on net sales generated from products or platforms developed using the licensed technology. 
• At the core of the deal is Datavault’s patented AI and blockchain infrastructure that enables secure tokenization and trading of high-value biomedical data and intellectual property. The platform aims to unlock new monetization pathways for biotech assets and create a digital marketplace where genomic, diagnostic, and therapeutic data can be exchanged more efficiently. 

Key Takeaways 

• The agreement positioned Datavault AI’s tokenization technology as an enabling infrastructure for digital biotech asset markets 
• Scilex gained exclusive access to AI-driven blockchain tools to develop a biotech data and asset exchange platform 
• The deal highlighted growing interest in leveraging blockchain and tokenization to unlock value from genomic, diagnostic, and pharmaceutical data assets 

18. ABL Bio Development and Commercialization Deal with Eli Lilly and Co. 

Deal Date: 12 Nov, 2025 

Deal Value: $2.6B  

• ABL Bio entered a license, research, and collaboration agreement with Eli Lilly and Company in November 2025 to develop multiple therapeutics using ABL Bio’s proprietary Grabody bispecific antibody platform. The collaboration gives Lilly rights to apply the technology across several therapeutic modalities and disease areas, particularly focusing on programs targeting cancer and central nervous system (CNS) disorders with high unmet medical needs. 
• Under the terms of the agreement, ABL Bio secured a total of ~$55M in initial R&D funding, including ~$40M in upfront payment and a ~$15M strategic equity investment from Lilly. The deal carries a potential total value of up to ~$2.6B, including development, regulatory, and commercial milestone payments, along with tiered royalties on net sales of any approved therapies arising from the collaboration. 
• The partnership centers on ABL Bio’s Grabody platform, particularly its Grabody-B technology designed to shuttle large-molecule therapeutics across the blood–brain barrier (BBB). By enabling improved delivery of biologics to the brain, the platform aims to address a key challenge in developing treatments for neurological diseases while supporting Lilly’s efforts to expand its pipeline of next-generation biologics. 

Key Takeaways 

• The deal validated ABL Bio’s Grabody platform as a scalable bispecific antibody and drug-delivery technology 
• Lilly gained access to a platform capable of enabling multiple therapeutic programs, particularly targeting CNS diseases 
• The collaboration underscored growing big-pharma interest in technologies that can overcome biological barriers such as the blood–brain barrier for next-generation biologics 

17. ABL Bio Development and Commercialization Deal with GSK 

Deal Date: 6 Apr 2025 

Deal Value: $2.82B  

• ABL Bio has entered into a global licensing agreement with GSK for its Grabody-B BBB shuttle platform to develop therapies targeting various novel pathways using antibodies, siRNA, & ASOs for neurodegenerative diseases. 
• Under the terms of the agreement, ABL Bio will receive up to ~£77.1M (~$100M) in upfront and near-term payments, including an immediate upfront payment of ~£38.5M, along with additional research milestone payments and potential program expansion fees. The deal carries a total potential value of up to ~£2.075B (~$2.6–2.7B) in development, regulatory, and commercialization milestones, plus tiered royalties on net sales of any successfully commercialized products. 
• The collaboration centers on ABL Bio’s Grabody-B platform, which is designed to enable therapeutic molecules to cross the BBB by targeting the insulin-like growth factor 1 receptor (IGF1R). This approach aims to overcome a major obstacle in neurological drug development by improving the delivery of biologics and nucleic-acid therapies into the brain, potentially enabling new treatments for diseases such as Alzheimer’s and Parkinson’s. 

Key Takeaways 

• The deal validated Grabody-B as a promising platform for delivering biologics across the blood–brain barrier 
• GSK gained access to a technology capable of enabling multiple CNS therapeutic programs across modalities 
• The collaboration highlighted growing industry focus on BBB-penetrating technologies to advance next-generation neurodegenerative disease treatments 

16. Valo Health Development and Commercialization Deal with Merck KGaA 

Deal Date: 20 Nov 2025 

Deal Value: $3B  

• Valo Health entered a strategic research, development, and commercialization collaboration with Merck KGaA, Darmstadt, Germany in November 2025 to discover and develop novel treatments for Parkinson’s disease and related neurological disorders. The partnership combines Valo’s AI-enabled human causal biology platform with Merck KGaA’s drug development capabilities to identify novel disease targets and accelerate the discovery of potential therapeutic candidates. 
• Under the terms of the agreement, Valo Health is eligible to receive upfront and potential milestone payments totaling over ~$3B, along with additional R&D funding and royalties on any successfully commercialized products arising from the collaboration. The financial structure reflects a multi-program partnership aimed at advancing several discovery and preclinical development programs targeting Parkinson’s disease. 
• The collaboration centers on Valo’s AI-driven drug discovery infrastructure, which integrates large-scale human data- including access to more than 17M de-identified patient records and biobank samples, to identify disease mechanisms and validate novel therapeutic targets. Using this human-centric approach, the partnership aims to generate optimized small-molecule candidates that could address the underlying biology of Parkinson’s disease and related neurological disorders. 

Key Takeaways 

• The deal highlighted growing pharmaceutical interest in AI-driven drug discovery platforms for complex neurological diseases 
• Merck KGaA gained access to Valo’s large-scale human data and causal biology platform to accelerate Parkinson’s drug discovery 
• The collaboration underscored the industry shift toward data-centric target discovery approaches to improve success rates in neurodegenerative disease R&D 

15. Syneron Technology Development and Commercialization Deal with AstraZeneca 

Deal Date: 21 Mar 2025 

Deal Value: $3.47B  

• Syneron Bio entered a strategic development and commercial licensing collaboration with AstraZeneca in March 2025 to discover and develop potential first-in-class macrocyclic peptide therapeutics for chronic diseases. The agreement grants AstraZeneca access to Syneron Bio’s proprietary Synova platform, an intelligent high-throughput macrocyclic peptide discovery system designed to generate novel therapeutics across disease areas including rare, autoimmune, and metabolic disorders. 
• Under the terms of the agreement, Syneron Bio is eligible to receive up to ~$75M in upfront and near-term milestone payments. The deal carries a potential total value of up to ~$3.4B in additional development and commercial milestone payments, along with tiered royalties on global net sales of any approved therapies arising from the collaboration. AstraZeneca will also make a strategic equity investment in the company. 
• The collaboration centers on Syneron Bio’s Synova platform, which enables high-throughput discovery and optimization of macrocyclic peptide therapeutics.  

Key Takeaways 

• The deal positioned Synova as a next-generation platform for discovering macrocyclic peptide therapeutics 
• AstraZeneca gained access to a technology capable of generating multiple drug candidates across chronic disease areas 
• The collaboration highlighted increasing big-pharma interest in macrocyclic peptide platforms targeting complex and difficult-to-drug biological pathways 

14. Solventum Business Unit Purchase Deal with Thermo Fisher Scientific  

Date: 25 Feb 2025 

Deal Value: $4.1B  

• Solventum entered into an agreement with Thermo Fisher Scientific in February 2025 for the sale of its Purification & Filtration business, marking a strategic divestiture aimed at sharpening Solventum’s focus on its core healthcare segments. The acquired business provides advanced filtration and membrane technologies used in biopharmaceutical manufacturing, medical technologies, and industrial applications, making it a complementary addition to Thermo Fisher’s bioprocessing portfolio. 
• Under the terms of the deal, Thermo Fisher agreed to acquire the business for approximately ~$4.1B in cash, with Solventum expecting around ~$3.4B in net proceeds primarily to reduce outstanding debt and strengthen its balance sheet. The transaction was completed in September 2025 for roughly ~$4.0B in cash before customary adjustments, following regulatory approvals and closing conditions. 
• The divested unit specializes in purification and filtration technologies used across bioprocessing workflows, including biologics manufacturing, healthcare filtration, and industrial membrane applications 

Key Takeaways 

• The deal strengthened Thermo Fisher’s bioprocessing portfolio with advanced filtration technologies used in biologics manufacturing 
• Solventum used the divestiture to accelerate its transformation strategy and reduce leverage following its spin-off from 3M 
• The acquisition highlighted growing demand for bioprocessing infrastructure supporting large-scale biologics and advanced therapy manufacturing 

13. RemeGen Development and Commercialization Deal with Vor Biopharma 

Date: 25 Jun 2025 

Deal Value: $4.12B  

• RemeGen entered into an exclusive global development and commercial licensing agreement with Vor Bio in June 2025, granting Vor Bio rights to develop and commercialize telitacicept outside Greater China (China, Hong Kong, Macau, and Taiwan). The collaboration allows Vor Bio to advance the late-stage autoimmune therapy globally, while RemeGen retains regional rights and benefits from downstream commercialization value. 
• Under the terms of the agreement, Vor Bio will provide an initial payment of ~$125M, consisting of ~$45M upfront and ~$80M in warrants to purchase Vor Bio common stock. The deal also includes potential regulatory and commercial milestone payments exceeding ~$4B, along with tiered royalties on future global sales of the therapy. 
• The collaboration centers on telitacicept, a dual-target recombinant fusion protein that inhibits the cytokines BAFF (BLyS) and APRIL- key regulators of B-cell survival involved in autoimmune diseases. 

Key Takeaways 

• The deal enables Vor Bio to pivot toward autoimmune disease therapeutics through a late-stage clinical asset 
• RemeGen monetizes global rights to telitacicept while retaining significant long-term value through milestones and royalties 
• The collaboration highlights increasing cross-border licensing of Chinese-developed biologics for global clinical development and commercialization 

12. Orna Therapeutics Development and Commercialization Deal with Vertex Pharmaceuticals 

Date: 7 Jan 2025 

Deal Value: $4.35B  

• Orna Therapeutics entered a strategic research, development, and commercial licensing collaboration with Vertex Pharmaceuticals in January 2025 to develop next-generation gene editing therapies for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The three-year partnership leverages Orna’s proprietary lipid nanoparticle (LNP) delivery technology to enable in vivo delivery of gene-editing components to hematopoietic stem cells, supporting the development of advanced genetic medicines for hemoglobinopathies. 
• Under the terms of the agreement, Orna Therapeutics will receive ~$65M in upfront payments, including a convertible note investment. The company is also eligible to receive up to ~$635M in preclinical, clinical, regulatory, and commercial milestone payments related to SCD and TDT programs. In addition, Vertex holds options to expand the collaboration to up to ten additional products, which could provide Orna with up to ~$365M in additional option fees and milestones per product (total 10 products), alongside tiered royalties on future net sales of resulting therapies. 
• The collaboration centers on Orna’s advanced lipid nanoparticle delivery platform designed to deliver RNA-based and gene-editing therapeutics beyond the liver and directly to hematopoietic stem cells 

Key Takeaways 

• The collaboration validates Orna’s LNP delivery technology for enabling next-generation in vivo gene editing therapies 
• Vertex gains access to a platform designed to improve delivery of gene-editing components to hematopoietic stem cells 
• The deal reflects growing industry focus on in vivo gene editing approaches for treating genetic blood disorders such as SCD and TDT 

11. Harbour BioMed Option Licensing Deal with AstraZeneca 

Date: 21 Mar 2025 

Deal Value: $4.68B  

• Harbour BioMed entered a global strategic option-to-license collaboration with AstraZeneca in March 2025 to discover and develop next-generation multi-specific antibody therapeutics. The partnership leverages Harbour BioMed’s proprietary Harbour Mice fully human antibody technology platform to generate novel antibodies targeting diseases across immunology, oncology, and other therapeutic areas. 
• Under the terms of the agreement, AstraZeneca obtained the option to license two preclinical immunology programs and may nominate additional targets for discovery under the collaboration. Harbour BioMed is eligible to receive up to ~$175M in upfront, near-term milestone, and option-exercise payments, along with a ~$105M equity investment from AstraZeneca representing about 9.15% ownership in the company. The deal also includes potential development and commercial milestone payments of up to ~$4.4B, plus tiered royalties on future net sales of any licensed therapies. 
• The collaboration centers on Harbour BioMed’s Harbour Mice antibody discovery platform, which generates fully human monoclonal antibodies in multiple formats, including heavy-chain-only antibodies and bispecific constructs. By combining this discovery engine with AstraZeneca’s clinical development and commercialization capabilities, the partnership aims to accelerate the development of next-generation biologics such as antibody-drug conjugates and immune cell engagers targeting high-unmet-need diseases. 

Key Takeaways 

• The deal validated Harbour BioMed’s Harbour Mice® platform as a powerful engine for next-generation antibody discovery 
• AstraZeneca gained access to a scalable antibody platform capable of generating multiple therapeutic programs 
• The collaboration highlighted continued big-pharma investment in platform-based biologics discovery to expand multi-specific antibody pipelines 

10. Zealand Pharma Development and Commercialization Deal with Roche 

Date: 12 Mar 2025 

Deal Value: $5.25B  

• Zealand Pharma entered an exclusive global development and commercial licensing collaboration with Roche in March 2025 to co-develop and co-commercialize petrelintide, a long-acting amylin analog for the treatment of overweight and obesity. The partnership aims to position petrelintide as a foundational therapy for weight management, both as a standalone treatment and in combination with Roche’s incretin-based asset CT-388 for cardiometabolic diseases. 
• Under the terms of the agreement, Zealand Pharma will receive ~$1.65B in upfront payments, including ~$1.4B at closing and ~$250M over the first two years of the collaboration. The deal carries potential milestone payments of up to ~$3.6B comprising ~$1.2B in development milestones and ~$2.4B in sales-based milestones, bringing the total potential value to approximately ~$5.3B. The companies will share profits and losses 50/50 in the US and Europe, while Roche holds exclusive commercialization rights in the rest of the world and will pay tiered double-digit royalties on global sales. 
• The collaboration centers on petrelintide, a once-weekly injectable amylin analog designed to regulate appetite and body weight by enhancing satiety and restoring sensitivity to the hormone leptin. The therapy is currently in P-II clinical development and is being evaluated both as a monotherapy and in combination with CT-388, Roche’s dual GLP-1/GIP receptor agonist, with the goal of delivering improved efficacy and tolerability in obesity treatment. 

Key Takeaways 

• The deal positioned petrelintide as a potential next-generation therapy in the rapidly expanding obesity drug market 
• Roche strengthened its cardiometabolic pipeline by combining an amylin analog with its incretin-based assets 
• The collaboration highlighted growing big-pharma investment in multi-mechanism obesity therapies to compete with leading GLP-1 treatments 

9. CSPC Pharmaceutical Option Licensing Deal with AstraZeneca 

Date: 13 Jun 2025 

Deal Value: $5.33B  

• CSPC Pharmaceutical Group entered an option-to-license research and development collaboration with AstraZeneca in June 2025 to discover and develop novel oral small-molecule therapies using CSPC’s AI-driven drug discovery platform. The partnership focuses on identifying preclinical candidates targeting multiple chronic disease indications, with CSPC responsible for conducting discovery research while AstraZeneca evaluates potential assets for further global development. 
• Under the terms of the agreement, AstraZeneca paid an upfront fee of ~$110M for access to the discovery platform and candidate programs. CSPC Pharmaceutical Group is eligible to receive up to ~$1.62B in potential development milestone payments and up to ~$3.6B in sales-based milestone payments if AstraZeneca exercises its licensing options and the programs progress successfully. The deal also includes tiered royalties on global net sales of any commercialized products. 
• The collaboration centers on CSPC’s AI-enabled dual-engine drug discovery platform, which accelerates target identification, molecule design, and optimization for oral small-molecule therapeutics. By combining this platform with AstraZeneca’s global clinical development and commercialization capabilities, the partnership aims to rapidly generate innovative drug candidates across multiple chronic disease areas, including immunological conditions. 

Key Takeaways 

• The deal highlights growing pharmaceutical interest in AI-driven platforms to accelerate small-molecule drug discovery 
• AstraZeneca gains early access to multiple preclinical programs with the option to license global development rights 
• The collaboration reflects increasing cross-border R&D partnerships between global pharma companies and Chinese biotech innovators 

8. Argo Biopharmaceutical Option Licensing Deal with Novartis 

Date: 3 Sep 2025 

Deal Value: $5.36B  

• Argo Biopharma entered a multi-asset option-to-license and development collaboration with Novartis in September 2025 to advance several siRNA-based therapeutics targeting cardiovascular diseases. The agreement expands the companies’ existing partnership and allows Novartis to access multiple assets from Argo’s pipeline, including discovery-stage candidates for severe hypertriglyceridemia and mixed dyslipidemia, as well as rights associated with additional cardiovascular programs. 
• Under the terms of the deal, Argo Biopharma will receive an upfront payment of ~$160M. The company is also eligible to receive potential options and milestone payments of up to ~$5.2B, along with tiered royalties on global net sales of any approved products. In addition, Novartis has expressed a non-binding intention to participate in Argo’s future equity financing round. 
• The collaboration centers on Argo’s RNA interference (siRNA) therapeutics platform designed to silence disease-causing genes involved in cardiovascular and metabolic disorders. The agreement includes a right of first negotiation for BW-00112, an ANGPTL3-targeting therapy currently in P-II clinical development for dyslipidemia, as well as an siRNA candidate in IND-enabling studies expected to enter P-I trials in 2026. 

Key Takeaways 

• The deal strengthens Novartis’ cardiovascular pipeline through access to multiple siRNA-based therapeutic programs 
• Argo Biopharma secures significant upfront capital while retaining long-term value through milestones and royalties 
• The collaboration highlights increasing big-pharma interest in RNA interference technologies for treating cardiometabolic diseases 

7. Monte Rosa Therapeutics Option Licensing Deal with Novartis 

Date: 13 Sep 2025 

Deal Value: $5.76B  

• Monte Rosa Therapeutics entered an option-to-license research and development collaboration with Novartis in September 2025 to discover and develop novel molecular glue degrader (MGD) therapies targeting immune-mediated diseases. The collaboration leverages Monte Rosa’s AI/ML-enabled QuEEN product engine to identify and develop degraders against difficult-to-drug immunology targets, while Novartis will lead later-stage development and global commercialization of selected programs.  
• Under the terms of the agreement, Monte Rosa Therapeutics received an upfront payment of ~$120M and will also receive option-maintenance payments for ongoing research programs. The company is eligible to receive up to ~$5.7B in total potential payments, including option exercise fees as well as development, regulatory, and sales milestones, along with tiered royalties on global net sales of any commercialized products.  
• The collaboration centers on Monte Rosa’s molecular glue degrader technology, which enables targeted protein degradation by directing the cell’s natural protein disposal system toward disease-causing proteins 

Key Takeaways 

• The deal validated Monte Rosa’s molecular glue degrader platform as a promising modality for targeting difficult immunology pathways 
• Novartis gained access to a discovery engine capable of generating multiple degrader-based therapeutic programs 
• The collaboration highlighted growing pharmaceutical interest in targeted protein degradation technologies for immune-mediated diseases 

6. XtalPi Development and Commercialization Deal with DoveTree 

Date: 6 Aug 2025 

Deal Value: $5.99B  

• XtalPi entered a development and commercial licensing collaboration with DoveTree Medicines in August 2025 to discover and develop novel therapeutics using XtalPi’s AI- and robotics-powered drug discovery platform. The partnership combines XtalPi’s computational and automated discovery technologies with DoveTree’s expertise in biological target identification and validation to generate first-in-class drug candidates across several therapeutic areas. 
• Under the terms of the agreement, XtalPi received an upfront payment of ~$51M and is eligible for an additional ~$49M in near-term payments. The deal carries potential development and commercial milestone payments of up to ~$5.89B, bringing the total potential value of the collaboration to approximately ~$5.99B, along with tiered royalties on future global sales of resulting therapies. 
• The collaboration centers on XtalPi’s integrated AI-driven drug discovery platform, which combines quantum physics simulations, machine learning algorithms, and robotic laboratory automation to accelerate molecule design and optimization.  

Key Takeaways 

• The deal positions XtalPi’s AI- and robotics-enabled discovery platform as a scalable engine for generating first-in-class drug candidates 
• DoveTree gains exclusive global rights to develop and commercialize therapies discovered through the collaboration 
• The partnership highlights the growing role of AI-driven drug discovery platforms in tackling complex and traditionally undruggable disease targets 

5. 3SBio Development and Commercialization Deal with Pfizer 

Date: 19 May 2025 

Deal Value: $6.3B  

• 3SBio entered an exclusive global development and commercial licensing agreement with Pfizer in May 2025 for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for the treatment of multiple solid tumors. Under the agreement, Pfizer obtained exclusive rights to develop, manufacture, and commercialize the therapy worldwide outside China, strengthening its oncology pipeline with a promising immuno-oncology asset.  
• Under the terms of the deal, 3SBio will receive ~$1.25B in upfront payment. The agreement includes potential development, regulatory, and commercial milestone payments of up to ~$4.8B as well as tiered double-digit royalties on sales of SSGJ-707, if approved, bringing the total potential value of the collaboration to more than ~$6B. In addition, Pfizer will make a ~$100M equity investment in 3SBio and holds an option to obtain commercialization rights for the therapy in China through additional option payments.  
• The collaboration centers on SSGJ-707, a bispecific antibody designed to simultaneously target PD-1 and VEGF – two key pathways involved in tumor immune evasion and angiogenesis 

Key Takeaways 

• The deal strengthens Pfizer’s oncology pipeline with a next-generation PD-1/VEGF bispecific antibody 
• 3SBio secures significant upfront capital while retaining long-term value through milestones and royalties 
• The collaboration highlights growing big-pharma interest in licensing innovative oncology assets from Chinese biotech companies 

4. Shanghai Fosun Pharmaceutical Option Licensing Deal with Clavis Bio 

Date: 19 Dec 2025 

Deal Value: $7.25B  

• Shanghai Fosun Pharmaceutical entered a five-year research collaboration and option-to-license agreement with Clavis Bio, a newly formed entity of Aditium, to co-develop novel therapies across multiple undisclosed indications. Under the partnership, both companies will jointly advance discovery and early research programs through preclinical development, while Clavis Bio will have the option to assume responsibility for further global development and commercialization outside China. 
• Under the terms of the agreement, Clavis Bio will propose up to four new therapeutic targets per year for joint research. If Clavis exercises its option to advance programs beyond preclinical development, it will obtain exclusive worldwide rights to develop and commercialize the therapies outside China, while Fosun Pharma will retain development and commercialization rights in China, Hong Kong, and Macau. Fosun is eligible to receive up to ~$362.5M per program in option exercise fees, development, and commercial milestone payments, plus royalties on sales, bringing the total potential value of the collaboration to up to ~$7.25B across 20 potential programs. 
• The partnership also introduces a venture-creation model in which Aditium will establish a new company for each program that moves forward into development. Fosun Pharma will hold a minority equity stake in each of these newly formed companies, enabling it to maintain long-term strategic and financial participation while Clavis Bio leads global development outside China. 

Key Takeaways 

• The deal establishes a venture-creation model to advance multiple therapeutic programs across global markets 
• Clavis Bio gains ex-China rights to develop and commercialize therapies emerging from the collaboration 
• The partnership reflects increasing cross-border R&D collaborations between Chinese pharmaceutical companies and global biotech venture platforms 

 3. BioNTech Development and Commercialization Deal with BMS 

Date: 6 Jun 2025 

Deal Value: $11.1B  

• BioNTech entered a global development and commercial licensing collaboration with Bristol Myers Squibb (BMS) in June 2025 to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A for the treatment of multiple solid tumors. The partnership combines BioNTech’s immuno-oncology innovation with BMS’s global oncology development and commercialization expertise to accelerate the clinical development and potential global launch of the therapy. 
• Under the terms of the agreement, BioNTech received ~$1.5B in upfront payment and will receive an additional ~$2B in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to ~$7.6B in development, regulatory, and commercial milestone payments, bringing the total potential value of the collaboration to over ~$11B. Both companies will share global development and manufacturing costs as well as profits and losses equally under a 50/50 profit-sharing structure. 
• The collaboration centers on BNT327, an investigational bispecific antibody designed to simultaneously block PD-L1 immune checkpoint signaling and VEGF-A-mediated angiogenesis. The therapy is currently being evaluated in multiple ongoing clinical trials-including global P-III studies for extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC)-with additional trials planned for other tumor types such as triple-negative breast cancer. 

Key Takeaways 

• The deal positions BNT327 as a potential next-generation immuno-oncology backbone therapy across multiple solid tumor indications 
• Bristol Myers Squibb strengthens its oncology pipeline through access to a dual-mechanism PD-L1/VEGF bispecific antibody 
• The collaboration highlights growing pharmaceutical investment in bispecific antibody therapies designed to improve outcomes beyond traditional checkpoint inhibitors 

2. Innovent Biologics Development and Commercialization Deal with Takeda 

Date: 21 Oct 2025 

Deal Value: $11.4B  

• Innovent Biologics entered a global development and commercial licensing collaboration with Takeda in October 2025 to advance multiple next-generation oncology therapies for solid tumors. The partnership grants Takeda rights to develop, manufacture, and commercialize two late-stage investigational medicines- IBI363 and IBI343, outside Greater China, while also securing an option to license an additional early-stage program, IBI3001. 
• Under the terms of the agreement, Innovent Biologics will receive ~$1.2B in upfront payment, including a ~$100M equity investment from Takeda. The deal also includes potential development and commercial milestone payments of up to ~$10.2B, bringing the total potential value of the collaboration to approximately ~$11.4B, along with tiered royalties on future global sales of the therapies. 
• The collaboration centers on IBI363, a bispecific antibody fusion protein being evaluated in non-small cell lung cancer and colorectal cancer, and IBI343, an antibody-drug conjugate targeting Claudin 18.2 for gastric and pancreatic cancers. Takeda will lead global co-development and US co-commercialization of IBI363 and hold exclusive commercialization rights outside the US and Greater China, while also obtaining global rights to develop and commercialize IBI343 outside Greater China. 

Key Takeaways 

• The deal strengthens Takeda’s oncology pipeline with late-stage immuno-oncology and ADC assets targeting solid tumors 
• Innovent secures significant upfront capital while retaining long-term value through milestones and royalties 
• The collaboration highlights growing global demand for innovative oncology assets originating from Chinese biotech companies 

1. Jiangsu Hengrui Pharmaceuticals Development and Commercialization Deal with GSK 

Date: 27 Jul 2025 

Deal Value: $12.5B  

• Jiangsu Hengrui Pharmaceuticals entered a development and commercial licensing collaboration with GSK in July 2025 to advance up to 12 innovative therapeutic programs across respiratory, immunology & inflammation, and oncology. The agreement includes an exclusive worldwide license (excluding mainland China, Hong Kong, Macau, and Taiwan) for HRS-9821, a potential best-in-class PDE3/4 inhibitor currently in clinical development for COPD  
• Under the terms of the agreement, GSK will pay approximately ~$500M in upfront fees across the collaboration. Hengrui Pharma is also eligible to receive up to ~$12B in potential development, regulatory, and commercial milestone payments if all programs are successfully advanced and licensed, along with tiered royalties on future global product sales outside the retained territories.  
• The collaboration centers on HRS-9821, a dual phosphodiesterase-3/4 inhibitor designed to deliver bronchodilation and anti-inflammatory effects for patients with COPD. The therapy has shown promising activity in early clinical and preclinical studies and is being explored as an add-on maintenance treatment delivered via a dry-powder inhaler, aligning with GSK’s established respiratory portfolio. In addition to this asset, Hengrui will lead early development of up to 11 additional programs through Phase I, after which GSK may exercise options to advance them globally.  

Key Takeaways 

• The deal strengthens GSK’s pipeline in respiratory, immunology, inflammation, and oncology with access to up to 12 innovative programs 
• Hengrui Pharma secures significant upfront funding while retaining long-term value through milestones and royalties 
• The collaboration reflects growing cross-border licensing activity as global pharma companies seek innovative assets from Chinese biotech pipelines 

  Sources:  

• DealForma Biopharma Deals Database 
• Company Websites   
• SEC Filings  

Related Post: Top 20 Life Sciences Deals of 2024 by Total Deal Value